Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and Representative Director: Gyo Sagara;) today announced that it has revised its consolidated financial forecasts for the full-year period ending March 2022 disclosed at the announcement of financial results ended March 2021, made on May 11, 2021, as follows:

1. Revisions to the Full-Year Consolidated Financial Forecasts Ending March 2022
   (April 1, 2021 - March 31, 2022)

   (Millions of yen, except Basic earnings per share)

   	Revenue	Operating profit	Profit before tax	Profit for the year	Profit for the year attributable to owners of the Company	Basic earnings per share (yen)
   Previous Forecast (A)	350,000	105,000	107,000	83,100	83,000	166.29
   Revised Forecast (B)	345,000	103,000	105,000	81,600	81,500	163.28
   Change (B – A)	△5,000	△2,000	△2,000	△1,500	△1,500	-
   Change (%)	△1.4％	△1.9％	△1.9％	△1.8％	△1.8％	-
   (Reference) Results of the previous period	309,284	98,330	100,890	75,497	75,425	151.11

2. Reasons for Revisions

   　Taking into account the drug price recalculation of "Opdivo Intravenous Infusion", starting from August this year, decided at the Central Social Insurance Medical Council held on May 12, 2021, we have revised its revenue forecast downward from ¥120 billion to ¥110 billion. On the other hand, the revenue forecast for major products including new products other than "Opdivo Intravenous Infusion" has been revised upward. Consequently, we anticipate a decrease of ¥5 billion from the previously announced forecast to ¥345 billion.
   　Cost of sales is forecast to decrease by ¥1 billion from the previously announced forecast to ¥95 billion due to a decrease in revenue.
   　Selling, general and administrative expenses are expected to be ¥74 billion, a decrease of ¥2 billion from the previously announced forecast.
   　As a result of the above, operating profit is forecast to be ¥103 billion (decrease by ¥2 billion from the previous forecast), profit before tax ¥105 billion (decrease by 2 billion), profit for the year ¥81.6 billion (decrease by ¥1.5 billion), and profit attributable to owners of the Company ¥81.5 billion (decrease by ¥1.5 billion).

   (Note) The above financial forecasts and statements contained in this announcement are made based on information available as of the announcement date. Actual results may differ materially from those set forth in the announcements due to various uncertain factors.